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Abstract

IMPACT OF STATIN THERAPY ON OUTCOMES IN ANEURYSMAL
SUBARACHNOID HEMORRHAGE PATIENTS

By Abdulkhaliq Jassem Alsalman, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master at
Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr. Gretchen Brophy
Professor of Pharmacy and Neurosurgery

There is conflicting data on the effects of statins on cerebral vasospasm and clinical
outcomes in aneurysmal subarachnoid hemorrhage (aSAH) patients. In this retrospective
cohort study, patients were divided into those who received pravastatin (PRAV group)
40mg/d and those who did not (NP group). Data were analyzed using multivariate logistic

xv
regression. Eighty-one patients met inclusion criteria. There was a statistically significant
decreased in the incidence of vasospasm in the PRAV group; however, this association did
not retain significance after adjusting for WFNS, race, elevated WBC, and clipping (59%
PRAV vs. 88% NP, p=0.08). There was no statistically significant difference in proportion
of severe radiological vasospasm or mortality between groups. However, there was a trend
towards a decreased mean length of stay (P=0.06) and a significantly higher proportion of
survivors discharged to home in the PRAV group (P<0.0001). In conclusion, there was a
trend towards a decrease in the incidence of vasospasm in the aSAH receiving pravastatin,
but this trend did not achieve statistical significance after adjusting for potential
confounders. Pravastatin was associated with other favorable clinical outcomes.

CHAPTER 1 INTRODUCTION

Background and Significance
Subarachnoid hemorrhage (SAH) accounts for around 3-5% of all strokes. (1, 2)
Rupture of an intracranial aneurysm is the principal cause of nontraumatic SAH making
up approximately 80% of all SAH cases. (3-5)
The incidence of SAH from a ruptured aneurysm is approximately 7.8/100,000 to
21.4/100,000 (6, 7) with approximately 21,000 to 33,000 new cases of subarachnoid
hemorrhage each year in the US. (2, 8) The initial hemorrhage after aneurysmal
subarachnoid hemorrhage (aSAH) accounts for up to 50% of the death rate, (9) with an
anticipated 30% of patients having some kind of disability after SAH.(3, 5)
SAH is followed by histopathological damage to the cerebrovascular endothelium
and depletion of endothelium-dependent relaxation factors, leading to vasospasm (10),
which is one of the most dangerous complications following aneurysmal SAH. Cerebral
vasospasm is defined as “the delayed narrowing of large capacitance arteries at the base
of the brain after SAH, which is often associated with radiographic or cerebral blood flow
(CBF) evidence of diminished perfusion in the distal territory of the affected artery”. (11)
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Approximately 70% of SAH patients experience some degree of vasospasm, with
20–30% developing ischemic symptoms.(12, 13) The major reason for morbidity in
patients after the initial SAH is delayed cerebral ischemic (DCI) resulting from cerebral
vasospasm.(11, 12, 14) The fatality rate from vasospasm alone has been estimated to be
between 15% and 50%. (11, 15)

Factors Associated With Development of Vasospasm and DCI
Medical literature identified many factors that predict the occurrence of cerebral
vasospasm. Risk factors associated with the development of vasospasm and DCI are
advanced age, (16) race (17), female patients, (2, 18-20) poor neurological status on
admission, (21, 22) amount of exposure to subarachnoid blood, thick blood collections in
basal cisterns and fissures, and intraventricular blood, (22-26) a longer duration of
unconsciousness following the initial hemorrhage, (27) history of hypertension, (22, 2830) smoking, (31, 32) and a history of cocaine abuse. (33, 34)
Although the exact pathogenesis of vasospasm is not fully understood, studies
have suggested that cerebral vasospasm is most likely caused by nitric oxide (NO)
depletion, inflammation activation, free radical damage, (35-38) enhanced platelet
aggregation and leukocyte adhesion. (39) These effects can be provoked by blood
products that continue rubbing the cerebral vessel wall following aSAH. (40) (Figure 1)
Vasospasm usually occurs between days 4-7 days after aSAH. (12, 14) In patients with
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aSAH a high temperature, headache and leukocytosis are frequently present and may
indicate the beginning of vasospasm. (41, 42)

Figure 1: Suggested mechanism of vasospasm after aSAH. Liu-Deryke,
Pharmacotherapy 2006; 26:182-203 (43)

Diagnosis of vasospasm
Clinically, vasospasm can be identified through regular, comprehensive
neurological examinations. Signs and symptoms can include changes in level of
consciousness and mental status (measured by Glasgow Coma Scale [GCS]), severe
headache, disorientation, confusion, dysphasia, aphasia, hemiplegia, hemiparesis, and any
new motor deficits which are not due to seizure, hematoma, brain edema, hydrocephalus
and structural or metabolic causes. (44, 45) The neurological deficits related to
vasospasm may become temporary or permanent disabilities. (44) An increase in white
blood cells (WBC) is significantly associated with increased risk of cerebral vasospasm
after aSAH (46). Hypomagnesemia is common after aSAH and has been associated with
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poor outcome and vasospasm. (47) Hypomagnesemia on admission occurs in 38% of
individuals with aSAH. It is still controversial whether it predicts the development of
DCI (48, 49)
Cerebral vasospasm is determined radiologically by cerebral angiography and
transcranial doppler ultrasonography (TCD) velocity. (50) Angiography (including CT
angiography and magnetic resonance angiography) is the gold standard and the definitive
study for the diagnosis of cerebral vasospasm with a sensitivity of 98% to 100% in the
first 12 hours. (51-55) TCD imaging is a noninvasive technique often used to diagnose
vasospasm. TCD studies are done at the bedside, generally on semi daily basis. TCD
ultrasonography measures velocity of blood flow in cerebral arteries and can be useful in
identifying and observing the degree of cerebral vasospasm after aSAH. (11) Contraction
and tightening of the arterial lumen which takes place in cerebral vasospasm creates a rise
of blood flow velocity which could be identified with TCDs (56, 57). Serial screening
with TCDs currently is recommended for all patients with aSAH for the detection and
monitoring of vasospasm. (58) Despite the high variability of specificity and sensitivity
of TCD ultrasonography (50, 59-61), increasing blood flow velocities on serial TCD
studies are usually reliable indicators of vasospasm (62, 63) and the reliability of
recognizing the severity of cerebral vasospasm is high. (50, 64) Elevated blood-flow
velocities (≥120 cm/sec) or increases of >50 cm/sec indicate cerebral vasospasm. (65)
TCD findings are most reliable as predictors of vasospasm of the middle cerebral (MCA)
and internal carotid (ICA) arteries. (63) The standard velocities for the middle cerebral
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artery (MCA) are shown in Table 1. In order to distinguish vasospasm from hyperemia
(which raises blood flow velocities in both the MCA and the ICA) and to avoid
underestimating the number of patients having vasospasm, clinicians and researchers use
the ratio of these velocities (known as Lindegaard ratio) also shown below in table
(1).(66) The Lindegaard ratio is calculated bilaterally as the ratio of the MCA velocity to
the ipsilateral extracranial ICA velocity with ratios below 3 indicating no vasospasm.(66)
(Table 1)

Table 1: Interpretation of transcranial doppler for vasospasm severity (66)
Mean MCA velocity
(cm/sec)
<120
120-200
>200

MCA:ICA(Linegaard)ratio

Interpretation

<3
3-6
>6

Normal
Mild vasospasm
Severe vasospasm

Grading Scales in aSAH
The use of grading scales in aSAH patients is common. Several scales have been
used in order to assess prognosis and clinical outcomes after SAH. These include Fisher
Scale (FS), Hunt and Hess (HH) Scale, and the World Federation of Neurological
Surgeons (WFNS) Scale. These scales have been validated in patients with aSAH.
The Fisher CT grading scale is a helpful predictor of vasospasm.(23, 24) (Table 2)
Fisher et al. linked the location and thickness of subarachnoid blood on CT with clinical
outcome and possibility of emerging vasospasm. (67-70) Fisher classification is used to
grade the thickness of the subarachnoid clot. (24) A thick layer of subarachnoid blood
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and a poor initial clinical condition are known to elevate risk for poor clinical outcome,
delayed cerebral ischemia, and hypodense lesions on CT scanning consistent with
cerebral infarction.(11, 24, 30, 71) Previous studies have confirmed that Fisher grade was
a statistically significant factor associated with vasospasm. (21-23, 31)
The most commonly used scoring scales of severity of aSAH are the Hunt and
Hess grading (Table 3), (72, 73) and the WFNS (Table 5). (74-77) For both of these
scales, studies have indicated a direct correlation between the severity of the clinical
grade of cerebral aneurysm and the incidence of vasospasm after aSAH. (22, 78)
However, the interobserver agreement for the Hunt and Hess scale is poor (79).
The WFNS scale is a commonly used scale and classified based on GCS and
motor deficits. The Glasgow Coma Scale (GCS) is commonly used by clinician for
consciousness assessment. (Table 4) The total GCS is the sum of the subcategory scores
(eye, verbal, and motor response). A normal individual has a GCS = 15. A profoundly
comatose patient has a GCS=3. Although focal motor deficits are known to be predictive
of outcome after SAH, the GCS scale does not offer quantitative information related to
focal deficits, but WFNS does. (74-77) Furthermore, the WFNS scale has been validated
in patients with aSAH and commonly used to assess severity of brain injury upon
admission. (74-77)

7

Table 2: Fisher CT Grading Scale (24)
CT Fisher Grade
1

Description of CT SAH
No blood detected

2
3

Diffuse, thin layer (<1mm). Subarachnoid hemorrhage less than 1 mm thick
Localized clot or thick layer (>1mm). Subarachnoid hemorrhage more than
1 mm thick
Subarachnoid hemorrhage of any thickness with intra-ventricular
hemorrhage (IVH) or parenchymal extension
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Table 3: Hunt and Hess scale (72)
Grade
1
2
3
4
5

Description
Asymptomatic; or minimal headache and slight nuchal rigidity. Approximate
survival rate 70%.
Moderate to severe headache; nuchal rigidity; no neurologic deficit except cranial
nerve palsy. 60%.
Drowsy; minimal neurologic deficit. 50%.
Stuporous; moderate to severe hemiparesis; possibly early decerebrate rigidity
and vegetative disturbances. 20%.
Deep coma; decerebrate rigidity; moribund. 10%.
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Table 4: The Glasgow Coma Scale (80) for Mental Status Assessment
Eye opening
Spontaneous
In response to
speech
In response to pain
None
Best verbal
response
Oriented
conversation
Confused
conversation
Inappropriate words
Incomprehensible
sounds
None
Best motor
response
Obeys
Localizes
Withdraws
Abnormal flexion
Abnormal extension
None

4
3
2
1
5
4
3
2
1
6
5
4
3
2
1

Table 5: The World Federation of Neurosurgeons classification: (76)
WFNS Grade Glasgow Coma Scale (GCS) Score
1
15
2
13-14
3
13-14
4
7-12
5
3-6

Motor Deficit
Absent
Absent
Present
Present or absent
Present or absent
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Cerebral Vasospasm Classification
Because of the different ways of identifying cerebral vasospasm (clinically or
radiologically), cerebral vasospasm has been classified in different ways in the literature.
One of the most commonly described classifications of vasospasm is as the following:
(41, 45)
-

Absent (no clinical or radiological irregularity)

-

Asymptomatically present (radiological defect only) as the spasm can be evident
on angiograms without clinical vasospasm manifestation.

-

Symptomatically present (clinical and radiological irregularity or clinical
vasospasm only).

Aneurysm Treatment
Clipping the aneurysm or using endovascular coiling, within 72 hours of the
initial hemorrhage reduces the risk of acute rebleeding, may decrease the length of
hospital stay, (81, 82) and may be associated with lower rates of symptomatic vasospasm.
(83-86) However, some researchers found early surgery may increase the incidence of
secondary ischemia and a higher incidence of symptomatic vasospasm (87-89)
Cerebral Vasospasm Treatment
No definitive single treatment has been shown to manage cerebral vasospasm.
Nevertheless; there are three major supports for the prevention and treatment of cerebral
vasospasm after aSAH: calcium channel blockers, “triple H” therapy (hypertension,
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hypervolemia, and hemodilution), and endovascular procedures. Nimodipine is the
calcium channel blocker of choice and it is the only drug approved by the US Food and
Drug Administration for use in prevention and treatment of vasospasm. It is safe, costeffective and most importantly reduces the risk of poor outcomes and secondary ischemia
after aSAH. (90-97) Triple H therapy has become routine practice in many institutions,
and is considered the standard of care for treatment of cerebral vasospasm after aSAH
(83, 85, 98-100) The goal of Triple H therapy is to increase cerebral perfusion pressure,
improve blood flow to the brain, and decrease the risk of ischemia.(85, 103-107) The 3
elements of triple H therapy are hypertension, hypervolemia, and hemodilution. A
hypertensive state is carried on through the use of vasopressors and intropic agents such
as dopamine, phenylephrine, nonepinephrine, or dobutamine. Hypervolemia is achieved
by using volume expansion, which then produces hemodilution. Isotonic crystalloid
solutions and albumin have both been used to expand blood volume. (101) These
elements improve the symptoms of vasospasm more than treating the causes. (102) When
medical therapy (nimodipine and triple H therapy) is used and does not reverse ischemic
deficits, endovascular intervention with balloon angioplasty or direct arterial vasodilation
is indicated, (108-113) but may not be feasible in each institution. Another treatment
option that has been used is hypothermia. (114)
A new therapeutic alternative for patients with vasospasm after aSAH is “statin”
therapy. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have a well
recognized and powerful cholesterol-lowering activity. Previous experimental and
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clinical studies have demonstrated that statins also have pleiotropic effects. Statins
improve endothelial function and blood flow by promoting vasodilation by decreasing
vascular inflammation, vascular smooth muscle cell proliferation, superoxide free radical
formation, and platelet aggregation. It also up-regulates endothelial nitric oxide, which is
a powerful vasodilator, free radical scavenger, and an inhibitor of platelet aggregation,
vascular smooth muscle cell proliferation, and cell apoptosis. (115-119) Accordingly it
would be expected that statins may also decrease the incidence of cerebral vasospasm
after SAH and decreased its neurological complications.
Data from two small prospective clinical trials showed that treatment with
pravastatin or simvastatin for 14 days reduced cerebral vasospasm and vasospasm-related
ischemia. (120-122) Also, pravastatin 40mg therapy for 14 days has been shown to
reduce mortality in aSAH. (135). In a third prospective study, Chou et al. concluded that
simvastatin use for aSAH is safe and feasible but did not reach statistical significance.
(123) In one retrospective study Parra et al. demonstrated that statins lessened the
occurrence of delayed cerebral ischemia but outcome differences did not show a
statistically significant reduction in mortality rate (124). In another recent retrospective
study McGirt, et al. showed that statin treatment for 14 days had more than a 10-fold
reduction in the incidence of developing cerebral vasospasm after aSAH. (125) In
contrast to these studies, one retrospective study found that using statins may augment the
incidence of cerebral vasospasm. (126) Also, Kramer et al. found that simvastatin was not
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associated with a reduction in the incidence of vasospasm or improvement in outcomes.
(127)

Clinical Management Protocol for aSAH in Virginia Commonwealth University
Health System (VCUHS)
The treatments and procedures for aSAH patients have been consistent during the
study period (Jan 2000-June 2008) except for the addition of pravastatin 40mg per day as
standard therapy in 2005. The patient’s clinical condition at admission was usually
graded according to the Hunt and Hess, Fisher or WFNS classification system at our
institution. Patients with angiographic evidence of an aneurysm underwent surgical
clipping or endovascular coil embolization as early as possible. Nimodipine (60 mg every
4 hours for 21 days) was started on admission of every patient with aSAH. Triple H
therapy was started in patients under the suspicion of symptomatic vasospasm based on
the clinical judgment of the treating neurosurgn. Patients were typically given 0.9% NaCl
at a rate of 100-150 ml/hr, vasopressors drips (dopamine, phenylephrine, or
norepinephrine), and Albumin 5% solution (250 ml every 4-6 hours intravenously) if
vasospasm was diagnosed. Patients were monitored for vasospasm using TCD every
other day at the bedside and hourly GCS evaluation.
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Hypothesis
Pravastatin 40mg therapy given within 72 hours of aSAH for 21 days will reduce
the incidence of cerebral vasospasm; improve clinical outcomes and reduce mortality
following aSAH.

Rationale for Our Study
Overall, it appears that statin therapy for up to 14 days may decrease cerebral
vasospasm, decrease neurological and ischemic deficits, and reduce the morbidity and
mortality of aSAH patients. However, published studies only evaluated statin therapy for
duration of 14 days and a risk of rebound vasospasm have been suggested after
discontinuation of statin therapy at day 14. No studies to date have evaluated the
incidence of vasospasm following a 21-day course of statin therapy in aSAH patients.
Also, there is conflicting data on the effects of statins on cerebral vasospasm and clinical
outcome in aSAH patients. Studying an extended duration is reasonable based on the fact
that cerebral vasospasm and DCI onset peak between days 4-7, and can occur up to 21
days after aSAH. (12, 13, 40, 128-130)
The dose of pravastatin 40mg was chosen based on a previous study that showed
beneficial neuroprotective effects, decreased incidence of vasospasm and improved
patient outcomes in a phase II trial. (120) Although simvastatin is more lipophilic, the
previous studies did not show mortality benefit and, therefore, lipophilicity may not be a
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factor when determining effectiveness for prevention and treatment of vasospasm.
Additionally, this is the second study, which has focused exclusively on the effects of
pravastatin therapy.

Objectives
The objective of this retrospective-cohort study was to determine if pravastatin
therapy was associated with a decreased incidence of cerebral vasospasm and improved
outcomes (mortality, length of stay, and discharge disposition) in aSAH patients.

Specific Aims
1- To determine whether pravastatin reduced the incidence of cerebral vasospasm
after aSAH adjusting for potential confounders in multivariate logistic regression.
2- To assess the incidence the symptomatic vasospasm and asymptomatic vasospasm
between the two treatment groups (pravastatin and control)
3- To test the difference in the incidence of vasospasm between the duration of
pravastatin therapy variables (14 days or less and 15-21 days).
4- To assess the incidence of severe radiological vasospasm after aSAH between the
pravastatin-treated group and control group.
5- To assess the effects of pravastatin on the frequency and duration of Triple H
therapy after aSAH vasospasm.
6- To identify and assess the effect of other covariates (confounders) on cerebral
vasospasm after aSAH in our sample.
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7- To assess the effects of pravastatin on mortality after aSAH.
8- To assess the effects of pravastatin on the length of hospital stay and
neurosciences intensive care unit (NSICU) length of stay.
9- To assess the effects of pravastatin on survivor discharge disposition after aSAH.
10- To assess the effects of cerebral vasospasm on mortality, length of hospital stay
and survivors discharge disposition.
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CHAPTER 2 METHODS

Study Design
This is a retrospective-cohort study of Neuroscience ICU patients with aSAH.
This study was approved by the Virginia Commonwealth University Institutional Review
Board in September 2008.

Patients
All patients (18 years of age or older) with aSAH who were admitted to the
NSICU of VCUHS with the ICD-9 diagnosis code 430 (Subarachnoid Hemorrhage)
between January 2000 and June 2008 were identified, and patient charts were
retrospectively reviewed. Patient were divided into two groups, those who received
pravastatin 40mg per day (PRAV group [2005-June 2008]) and those who did not (NP
group [Jan 2000-Dec 2004]). Patients who presented within 48 hours of aneurysmal SAH
were assessed for the incidence of cerebral vasospasm after receiving pravastatin 40mg
per day or not receiving statin for 21 days. In the pravastatin group, patients were only
included if they received pravastatin 40mg within 72 hours of symptom onset.
Patients were excluded if they were diagnosed with nonaneurysmal SAH; were currently
taking statins as part of their home medication regimen; or were discharged from the
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NSICU or expire before post bleed day 3. We excluded patients participated in
investigational drug or procedures (Endovascular intervention for vasospasm included
either intra-arterial vasodilator administration or balloon angioplasty) intended to prevent
or treat vasospasm

Data Collection
Patient demographics, and baseline characteristics, if available in the patients’
charts, were collected. Data included medical history, social and family history, initial
aSAH grades on 48 hours admission or premorbid functional state (WFNS grade, Fisher
scale, Glasgow Coma Scale, and Hunt and Hess scale), medications on admission, time to
coil embolization of the aneurysm or to clip placements, and the occurrence of clinical
vasospasm. Moreover, we collected the APR-DRG grade as a predictor of survival,
hospital length of stay, and patient severity. (131-134) Documentation of the
hospitalization, clinical course, treatments, procedures, and complications were reviewed
and evaluated for each patient. Clinical outcomes were determined from documented
patient discharge disposition.
Laboratory Data
The following laboratory data were collected from the patient’s charts:
the white blood cell (WBC) count, magnesium levels, sodium serum level, and cardiactroponin-I. Lab results were evaluated for 21 days or until discharge.
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Elevated WBC: was defined as serum WBC > 11000 ng/dL on 2 consecutive
measurements.
Elevated Troponin-I: was defined as serum Troponin-I ≥ 2 mEq/L on 2
consecutive measurements.
Hypomagnesaemia: was defined as serum Mg++ < 1.3 mEq/L on 2 consecutive
measurements.
Hyponatremia: was defined as serum Na < 135 mEq/L on 2 consecutive
measurements.
Anemia: ICD-9 code for anemia and two consecutive hemoglobin concentrations
<10 g/dl.

Radiological Data:
The following radiological data were collected from the patient’s charts: presence
and severity of cerebral vasospasm, presence of hydrocephalus, aneurysm
location on cerebral angiography, and the TCD velocity values.
During the study period; there were no changes in the management of aSAH at
VCUHS (i.e. management parameters were standardized for all patients admitted
with aSAH). All patients underwent clip ligation or coiling within 72 hours of
aSAH. The clinical management of each patient included nimodipine for 21 days
and moderate intravenous fluid supplementation.
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Patient data were coded and de-identified. A key for the codes were stored
separately until all data were collected. The keys were destroyed after data
collection was completed.

Definitions:
Vasospasm was defined as either clinical or radiological. (Figure 2)
Definition of Radiological Cerebral Vasospasm
Patients will be considered to have radiological cerebral vasospasm if they had
TCD ultrasonography flow velocities that are double of the baseline value or are ≥ 120
cm/second; or have vasospasm as demonstrated on cerebral angiography. (Figure 2)

Definition of Symptomatic (Clinical) Cerebral Vasospasm
Patients were considered to have clinical cerebral vasospasm if they received 2 of
the 3 aspects of triple-H therapy (fluid>100ml/hr, albumin every 6hours and /or
vasopressor therapy) and a drop in GCS by ≥ 2 points (not due to drug effect), or acute
change of neurological status related to cerebral vasospasm. Also, patients were
considered to have clinical vasospasm if they had radiologic evidence of vasospasm and a
corresponding drop in GCS. (Figure 2 and 3)
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Classification of Cerebral Vasospasm
Cerebral vasospasm has been classified as asymptomatic and symptomatic
vasospasm. Asymptomatically present (radiological defect only without the happening of
clinical vasospasm manifestation) or symptomatically present (clinical and radiological
irregularity or clinical vasospasm only). The combination of radiological (TCD velocity
or angiography) and clinical diagnosis is a powerful predictor of vasospasm and poor
outcome.

Figure 2: Cerebral Vasospasm Definition
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Figure 3: Definition of clinical vasospasm

Definition of Severe Vasospasm
Patients were to have considered having severe cerebral vasospasm if their
TCD>200 cm/sec or their angiography report stated severe vasospasm. (Figure 4)

Figure 4: Severe cerebral vasospasm definition
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Outcome Measures
The primary outcome end point was the incidence of cerebral vasospasm. The
secondary outcome end points were incidence of symptomatic and asymptomatic
vasospasm, length of triple H therapy, incidence of severe vasospasm, mortality, length
of hospital stay, and survivor discharge disposition (rehabilitation, home, skilled facility).
(Figure 5)

Figure 5: Discharge disposition stratification

Sample Size Calculation
Our sample size calculation was built on a binomial model. From the Lynch et al
study, the incidence of vasospasm with control was 60% and with simvastatin was 26%.
Using nQuery Advisor software, a two-group continuity corrected χ2 test with a 0.05
two-sided significance level would have 80% power to detect the difference between a
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Group 1 proportion, π, of 0.60 and a Group 2 proportion, π, of 0.26 (odd ratio of 4.269)
when the sample size in each group is 38. Therefore, based on our calculation, the
minimum sample size in each arm is 38.

Statistical Analysis
The baseline demographics and the clinical characteristics of the study population
were described by frequencies, chi square, mean, and standard deviation. The
significance of differences in continuous variables was performed using the Student t-test
for normally distributed data. The Wilcoxon rank-sum test was used for continous data
that was not normally distributed data. Frequencies were analyzed using the chi-square
test. We compared the demographic and clinical characteristics of the subjects on
admission between the two treatment groups and all baseline demographics were tested
for univariate associations. They were considered statistically significant when the P
value was <0.05. P values were 2-sided. The association of pravastatin therapy with
incidence of cerebral vasospasm and the secondary outcomes were analyzed using
logistic regression to identify factors that may have affected the outcome. The adjustment
plan was for the following covariates: patient age, gender, race, WFNS grade, Hunt and
Hess grade, Fisher grade, Hunt and Hess, history of hypertension, other cardiovascular
disease, other probable conditions causing neurological deterioration (e.g.,
hydrocephalus, intracerebral hemorrhage, intraventricular bleeding and intraparenchymal
bleeding, subdural hemorrhage, and hyponatremia), tobacco use, excessive alcohol
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intake, history of cocaine use, clinical condition on admission and before surgery,
aneurysm location; and timing of aneurysm surgery. Univariate analysis was performed
to determine the variables that predicted our outcome (vasospasm). To control for
potential interaction among variables, a logistic regression model was created. We
identified demographic, clinical, and determined the strength of association of vasospasm
with the use of pravastatin, examined associations with hospital length of stay, mortality,
and discharge disposition. All analyses were performed using JMP Version 8 (latest
version).

Screening and Building the Multivariate Model
Choosing which variables to take in a model is not clear, especially in the case
aSAH. For the purpose of building a multivariable model, we have chosen to include the
risk factor and possible confounding variables that have been shown in past studies to be
confounders. We tried not to be strict in including the relevant variables in the analysis;
and we excluded any irrelevant factors or any factors that were not directly connected to
vasospasm. We also excluded variables with more than 8 missing data. We first ran
explanatory steps in order to describe the association of each predictor to the outcome
variable (vasospasm) and to avoid the possibility of having variables that were weakly
associated with the outcome when examined individually, but were strongly related with
outcome when examined together. The entrance criteria were p-value ≤ 0.2. Then we
tried to decrease the number of variables in order to obtain a simple final model by using
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automatic variable selection analysis (Forward stepwise regression building analysis)
with entry criteria of significance level at 0.2. Then we summarized the results of the
analysis with statistically significant variables (race, clipping, WFNS score, and elevated
WBC) in the model.

Interaction and Lack of Fit Test
The lack of fit test for this multivariate’s model was used to determine if higher order
model is indicated. If the lack of fit test for this multivariate’s model is statistically
significant, then higher order model is indicated.

CHAPTER 3 RESULTS

Demographics and Clinical Characteristics
The total number of study patients was 81. A total of 42 patients were included in
the NP group, and 39 patients were included in the PRAV group (pravastatin 40mg).
(Figure 3) Descriptive demographic data and clinical characteristics of our sample are
listed in Table 6. We tested for the difference of our covariates across the PRAV and the
NP groups to examine if the two groups were different at baseline. Approximately 80%
(n= 65) of our sample was female. The proportion of female patients was not statistically
different between the groups. Approximately 60% (n= 49) of our sample was African
American. The mean of age was 51 years (SD= 12.1) and approximately 55% (n= 45)
were less than age 55. Sixty-two percent of our sample (n= 50) were admitted with
WFNS grade 1 or 2, and 60% (n= 48) had a history of hypertension. Ninety percent of
our sample were clipped or coiled. The time to surgery was less than 72 hours for 98%
(n= 70) of patients who had surgery. Between the two treatment groups, there was no
statistically significant difference in the mean age. In addition, there was no statistically
significant difference in the proportions of the following covariates: gender, race, WFNS
grade, severity grades, history of tobacco, cocaine use, alcohol use, elevated WBC,
hypomagnesemia, hyponatremia, hypertension, hydrocephalus, myocardial infarction,
26
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seizure, intraparenchymal hemorrhage, intracerebral hemorrhage, intraventricular
hemorrhage, subdural hemorrhage, atrial fibrillation, anemia, or heart failure.
However, there was statistically significant difference between the groups in regards to
type of surgery, troponin-I, elevated WBC, and number of comorbidities. The proportion
of clipped patients and the proportion of patients with elevated troponin-I on admission
were significantly higher in the NP group versus the PRAV group (P <0.0001, P= 0.0028
respectively). The proportion of patients who had more than one comorbidity and the
proportion of patients who had surgery after 72 hours or had no surgery were
significantly higher in the PRAV group versus NP group (P=0.006, P=0.002,
respectively) (Figure 6)

Figure 6: Enrollment Flow Diagram
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Medians of GCS scores at Admission between the Two Treatment Groups
The median of GCS score in the two treatment groups was 14 (Range 3-15) in NP
versus 15 (Range 3-15) in PRAV. Using Wilcoxon test, there was no statistically
significant difference in the medians of GCS scores across the two treatment groups (P
=0.391). (Figure 7)

Figure 7: Difference of Median of GCS scores across the Two Groups
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Table 6: Descriptive Demographics and Clinical Characteristics
Count
Gender
Female
Male
Race
African American (AA)
Non- AA*
Co-morbidities
0 or 1
>1
WFNS
I or II
III-V
Severitya
Minor to Moderate
Major- Extreme
Tobaccoa
Y
N
Cocainea
Y
N
Alcohola
Y
N
Aneurysm Location
Anterior
Posterior
Clipped
Yb
Nc
Time to Surgery
<72hrs
>72hrs or no surgeryc
Elevated WBC
Y
N
Elevated Troponin-Ia
Y
N
Hypomagnesemia
Y
N
Hyponatremia
Y
N
Hypertension
Y
N
Hydrocephalus
Y
N

PRAV
%

Count

NP
%

N

X2

P

31
8

80
20

34
8

81
19

65
16

0.027

0.869

22
17

56
44

27
15

64
36

49
32

0.525

0.469

16
23

41
59

30
12

71
29

46
35

7.735

0.006

27
12

69
31

23
19

55
45

50
31

1.792

0.181

6
31

16
84

5
22

19
81

11
53

0.224

0.809

22
13

63
37

25
14

64
36

47
27

0.012

0.912

3
31

9
91

2
30

6
94

5
61

0.156

0.693

16
19

46
54

17
20

46
54

33
39

0.000

0.984

33
6

85
15

38
4

90
10

71
10

0.642

0.423

20
19

51
49

41
1

98
2

61
20

23.350

<0.0001

29
10

74
26

41
1

98
2

70
11

9.322

0.002

34
5

87
13

36
6

86
14

70
11

0.037

0.848

7
21

25
75

17
9

65
35

24
30

8.905

0.002

0
39

0
100

1
41

2
98

1
80

0.940

0.332

10
29

26
74

7
35

17
83

17
64

0.982

0.321

27
12

69
31

21
21

50
50

48
33

3.098

0.078

11
28

28
72

11
31

26
74

22
59

0.041

0.839
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Diabetes Mellitus
Y
N
Myocardial Infarction
Y
N
Seizure
Y
N
Intraparenchymal
Hemorrhage
Y
N
Intracerebral
Hemorrhage
Y
N
Intraventricular
Hemorrhage
Y
N
Subdural Hemorrhage
Y
N
Atrial Fibrillation
Y
N
Anemia
Y
N
Heart Failure
Y
N
Age

8
31

20
80

4
38

10
90

12
69

1.935

0.164

2
37

5
95

5
37

12
88

7
74

1.176

0.278

9
30

23
77

6
36

14
86

15
66

1.036

0.309

2
37

5
95

2
40

5
95

4
77

0.006

0.939

4
35

10
90

1
41

2
98

5
76

2.166

0.141

5
34

13
87

2
40

5
95

7
74

1.663

0.197

0
39

0
100

1
41

2
98

1
80

0.940

0.332

2
37

5
95

2
40

5
95

4
77

0.006

0.939

5
34

13
87

1
41

2
98

6
75

3.080

0.073

2
37
Mean
53.20

5
95
SD
10.81

0
42
Mean
49.59

0
100
SD
13.07

2
79

2.208

0.137

t-test
8.902

p-value
0.179

* Three were Hispanic, one was other and 28 were Caucasians
a
Variable had missing data
b
8 patients were clipped and coiled during the same admission
c
There were 9 patients had no surgery
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The Crude Analysis of the Effect of Pravastatin 40mg on the Incidence of Cerebral
Vasospasm
Approximately 75% (n= 60) of our study patients experienced cerebral
vasospasm. In the NP group 88% experienced vasospasm and in the PRAV group 59%
experienced vasospasm. (Table 7, Figure 8.) Using Pearson chi-square test, there was a
statistically significant difference in the proportion of cerebral vasospasm between the
two groups (P =0.0028), with the NP group having a significantly higher incidence of
cerebral vasospasm.
Table 7: Cerebral Vasospasm by Treatment Groups
NP
PRAV

VSP
37
(88%)
23
(59%)
60

No VSP
5
(12%)
16
(41%)
21

Total
42
39
81

Incidence of Vasospasm
100%
80%

n= 37

60%
n= 23

40%
20%

n= 5

n= 16

VSP

0%
NP (N=42)

No VSP

PRAV (N =39)
Treatment Groups
P=0.0028
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Figure 8: Incidence of Vasospasm between the Treatment Groups

Incidence of Vasospasm Stratified by Duration of Pravastatin Use
The mean duration of pravastatin use was 13.80 days (± 6.338) and the median
was 12 days (range 19 days). The percentage of patients who completed 20 or 21 days of
pravastatin 40mg daily was 36% (n= 14). Using t-test, there was no association between
the duration of pravastatin use and the incidence of vasospasm in the PRAV group
(P=0.263). We also categorized the duration of use into two categories (14 days or less
and 15-21 days of pravastatin use) in order to test the difference between the two periods;
46% (n= 18) were in the 15-21 day period. Using Pearson chi-square test, there was no
statistically significant difference in the incidence of cerebral vasospasm between the two
periods (P=0.37). (Table 8, Figure 9.)
Table 8: Incidence of Vasospasm by
Categories of Duration of Pravastatin Use
15-21
<14

VSP
12
(67%)
11
(52%)
23

No VSP
6
(33%)
10
(48%)
16

Total
18
21
39
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Incidence of Vasospasm Stratified by Duration of
Pravastatin Use
100%
80%
60%

n=12
n=11

40%
20%
0%
15‐21 days (N=18)

≤ 14 days (N=21)

Duration Categories of Pravastatin Use
P=0.37

Figure 9: Incidence of Vasospasm Stratified by Duration of Pravastatin Use

Clinical and Radiological Vasospasm Diagnosis Stratification
Sixty-four percent (n=52) of the study patients experienced clinical symptoms of
vasospasm; 70% (n= 36) of them were among the NP group. The overall stratification of
vasospasm diagnosis can be found in Figure 10. The clinical vasospasm diagnosis
stratification can be found in Figure 11. The radiological vasospasm diagnosis
stratification can be found in Figure 12.
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Distributtion of Ove
erall Vasosspasm Diaggnosis
100
0%
80
0%

87%

74%

64%

60
0%
40
0%
1
10% 13%

20
0%

Among all patients
(n=81)
Among vasospasm
patientss (n=60)

0
0%
VSP (n=60)
(

Symptomatic
(n=52)

Asympto
omatic
(Radiologiccal only)
(n=8
8)

Figurre 10: Overrall Stratificcation of Vaasospasm Diiagnosis

Stratificcation of Clinical Vasosp
pasm Diagno
osis

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

87%

79%
%

17%
4%

Clinical (n=52)

Symptoms+TTriple GCS+Radiological Sym
mptoms+Triplee
H+GCS (n=4
41)
(n
n=9)
H without GCS
(n=2)

Figurre 11: Strattification of Clinical Vaasospasm Diiagnosis
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Stratiification o
of Radiological Vaasospasm
m Diagnossis

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

87%

40%

46%

14%

Raadiological
(n=52)

TCD+Angiograaphy
(n=21)

TCD only(n=24) Anggiography only
(n=7)

Figurre 12: Strattification of Radiologicaal Vasospassm Diagnosiis

Compparison betw
ween the Treeatment Grooups in Sympptomatic an
nd Asymptom
matic
Vasospasm
Using Peaarson chi-squuare test, am
mong vasospasm patientss, there was a statisticallyy
signifficant differeence in the proportion
p
off symptomattic vasospasm
m patients between
b
the
two groups
g
(P=0.002), with a significantlly higher inccidence in thhe NP group.. About 10%
%
(n= 8)
8 of our patiients, which was approxiimately 13%
% of cerebrall vasospasm patients, hadd
radiological evideence of vasoospasm withoout having clinical
c
vasosspasm sympptoms
(asym
mptomatic vaasospasm). Seven of theem were amoong the PRA
AV group annd one was inn
the NP
N group. (Table 9 and Figure
F
13)
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Table 9: Symptomatic and Asymptomatic VSP by Treatment Groups
NP
PRAV

Asymptomatic
1
(3%)
7
(30%)
8

Symptomatic Total
36
37
(97%)
16
23
(70%)
52
60

Symptomatic and Asymptomatic Vasospasm by Treatment Groups
100%
n=36

80%

n=16

60%
40%
n=7
20%

Asymptomatic
Symptomatic

n=1
0%
NP (N=37)

PRAV (N=23)
Treatment Groups
P=0.002

Figure 13: Symptomatic and Asymptomatic Vasospasm by Treatment Groups
Results of Screening and Building the Multivariate Model
The Association of Cerebral Vasospasm and Potential Covariates
The characteristics of patients, based on whether or not they experienced
vasospasm are described in Table 10. Some variables were not included in the
multivariate model because they did not meet the criteria of being associated at a P value
less than 0.2 (Table 10). The ones that did meet these criteria were included in a
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multivariate regression model with vasospasm as the outcomes variable. The predictors
tested were race, clipped, elevated WBC, elevated troponin-I, hydrocephalus, and the
pravastatin treatment group. We included WFNS because it is correlated with aSAH
outcomes.
Table 10: Primary Outcome Univariate Analysis

Gender
Female
Male
Race
African American (AA)
Non-AA*
Co-morbidities
0 or 1
>1
WFNS
I or II
III-V
Severitya
Minor to Moderate
Major- Extreme
Tobaccoa
Y
N
Cocainea
Y
N
Alcohola
Y
N
Aneurysm Location
Anterior
Posterior
Clippedb
Y
Nc
Time to Surgery
<72 hrs
>72 hrs or no surgeryc
Elevated WBC
Y
N
Elevated Troponin-Ia
Y
N
Hypomagnesaemia
Y
N
Hyponatremia
Y
N

Vasospasm
Count

%

No-Vasospasm
Count
%

N

X2

P

47
13

78
22

18
3

86
14

65
16

0.535

0.465

39
21

65
35

10
11

48
52

49
32

1.966

0.161

35
25

58
42

11
10

52
48

46
35

0.225

0.636

35
25

58
42

15
6

71
29

50
31

1.863

0.394

7
37

16
84

4
16

20
80

11
53

2.171

0.367

35
20

64
36

12
7

63
37

47
27

0.001

0.970

4
44

8
92

1
17

6
92

5
61

0.144

0.704

25
27

48
52

8
12

40
60

33
39

0.350

0.538

45
6

90
10

17
4

81
19

71
10

1.177

0.278

51
9

85
15

10
11

48
52

61
20

11.690

0.001

56
4

93
7

13
8

62
38

69
12

0.386

0.535

55
5

92
8

15
6

71
29

70
11

5.429

0.020

21
20

51
49

3
10

23
77

24
30

3.166

0.075

1
59

2
98

0
21

0
100

1
80

0.354

0.552

11
49

18
82

6
15

29
71

17
46

0.983

0.321
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Hypertension
Y
N
Hydrocephalus
Y
N
Diabetes Mellitus
Y
N
Myocardial Infarction
Y
N
Seizure
Y
N
Intraparenchymal
Hemorrhage
Y
N
Intracerebral Hemorrhage
Y
N
Intraventricular
Hemorrhage
Y
N
Subdural Hemorrhage
Y
N
Atrial Fibrillation
Y
N
Anemia
Y
N
Heart Failure
Y
N
Pravastatin 40mg
Y
N
Age at arrival

34
26

57
43

14
7

67
33

48
33

0.644

0.422

19
41

32
68

3
18

14
86

22
59

0.041

0.123

10
50

17
83

2
19

10
90

12
69

0.629

0.428

6
54

10
90

1
20

5
95

7
74

0.541

0.462

13
47

22
78

2
19

10
90

15
66

1.520

0.218

3
57

5
95

1
20

5
95

4
77

0.002

0.965

3
57

5
95

2
19

10
90

5
76

0.550

0.459

4
56

7
93

3
18

14
86

7
74

1.144

0.285

1
59

2
98

0
21

0
100

1
80

0.354

0.552

3
57

5
95

1
20

5
95

4
77

0.002

0.965

3
57

5
95

3
18

14
86

6
75

3.080

0.162

1
59

2
98

1
20

5
95

2
79

0.619

0.432

23
37
Mean
50.46

38
62
SD
12.69

16
5
Mean
53.83

76
24
SD
10.08

39
42

8.930

0.0028

t-test
8.902

p-value
0.226

* Three were Hispanic, one was other and 28 were Caucasians
. Variable had missing data
b
. 8 patients were clipped and coiled at the same admission
c
. There were 9 patients that had no surgery

a

81

39

A multivariate analysis was conducted, adjusting for the following covariates: race,
WFNS, elevated WBC, and aneurysm clipping. (Table 11)
Table 11: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Cerebral Vasospasm following SAH
Variable

Chi Square

Odd ratio

Lower CI

Upper CI

p-value

Pravastatin

3.014

0.278

0.058

1.180

0.082

Race (non- AA*)

1.653

0.453

0.130

1.519

0.198

Elevated WBC

5.174

6.140

1.284

34.605

0.023

Clipped

1.941

2.690

0.668

11.336

0.163

WFNS ( III-V)
*AA=African American

0.462

1.565

0.434

6.184

0.496

The logistic regression model showed no statistically significant difference in the
proportion of cerebral vasospasm across the two treatment groups (P=0.082). The odds of
developing vasospasm in the PRAV group were less than the NP group, but it was not
statistically significant. The odds of having vasospasm in Non- African American
patients were less than the African American patients, but it was not statistically
significant. Patients with elevated WBC counts had a 6-fold increase in the odds of
developing vasospasm. Furthermore, the odds of developing vasospasm in clipped
patients were higher than non-clipped patients, but it was not statistically significant. The
odds of developing vasospasm in patients with WFNS scores of III-V were higher than
patients with WFNS scores of I-II, but it was not statistically significant.
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Interaction and Lack of Fit Test
Since the lack of fit test for this multivariate’s model was not statistical
significant, no higher order model is indicated.

Multivariate Analysis Model without Including Clipping Surgery
Because of collinearity (98% of NP group were clipped) and in order to check
which variable has the most impact on vasospasm, we reran the analysis without
including the clipping as a covariate. A multivariate nominal logistic regression was fit
with effects of race, WFNS, and elevated WBC. (Table 12) The logistic regression model
showed a statistically significant difference in the proportion of cerebral vasospasm
across the two groups (PRAV and NP) (p=0.005) when clipping was removed from the
model. The proportion having cerebral vasospasm was lower in the pravastatin group.
However, the p-value for pravastatin 40mg effect on reducing vasospasm remained
insignificant when any of the following covariates were removed: elevated WBC, WFNS,
non-African-American race in the presence of clipping effect.
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Table 12: Multivariate Analysis Model without Including Clipping Surgery
Variable

Chi Square

Odd ratio

Lower CI

Upper CI

P-value

Pravastatin

9.448

0.164

0.041

0.535

0.002

Race (non-AA*)

2.560

0.389

0.115

1.236

0.110

Elev. WBC

6.464

7.150

1.565

39.173

0.011

WFNS (III-V)

0.398

1.494

0.432

5.595

0.528

*AA=African American

Incidence of Vasospasm in the Clipped Patients
Using Pearson chi-square test, in the clipped patients, there was no statistically
significant difference in the proportion of vasospasm between in the two treatment groups
(p=0.21). (Table 13 and Figure 14)

Table 13: Cerebral Vasospasm in Clipped Patients
NP
PRAV

VSP
36
(88%)
15
(75%)
51

No VSP
5
(12%)
5
(25%)
10

Total
41
20
61
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Incidence of Vasospasm in Clipped Patients
90%
n=36

85%
80%
75%

n=15

70%
65%
NP (N=41)

PRAV (N=20)
Treatment Groups
P=0.21

Figure 14: Incidence of Vasospasm in Clipped Patients
Incidence of Vasospasm in the Non-Clipped Patients
Using Pearson chi-square test, in the non-clipped patients, there was no
statistically significant difference in the proportion of vasospasm between the two groups
(p=0.257). (Table 14 and Figure 15)
Table 14: Cerebral Vasospasm in Non-Clipped patients
NP
PRAV

VSP
1
(100%)
8
(42%)
9

No VSP
0
(0%)
11
(58%)
11

Total
1
19
20

43

Incidence of Vasospasm in Non‐Clipped Patients
120%
100%
n=1

80%
60%
40%

n=8

20%
0%
NP (N=1)

PRAV (N=19)
Treatment Groups
P=0.257

Figure 15: Incidence of Vasospasm in Non-Clipped Patients

Incidence of Vasospasm by Type of Surgical Intervention in the PRAV Patients
Using Pearson chi-square test, among the pravastatin users, the proportion of
patients experiencing vasospasm was significantly higher in the clipped group as
compared to non-clipped group(p=0.037). (Table 15 and Figure 16)

Table 15: Cerebral Vasospasm by Type of
Surgical Intervention in the PRAV Patients
Non-Clipped
Clipped

VSP
8
(42%)
15
(75%)
23

No VSP Total
11
19
(58%)
5
20
(25%)
16
39
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Incidence of Vasospasm by Type of Surgical
Intervention in the PRAV Patients
80%
n=15

60%
40%

n=8

20%
0%

Non‐Clipped

Clipped

Surgical Intervention Groups
P=0.037

Figure 16: Vasospasm across Surgical Intervention Groups in the PRAV Group
Radiological Confirmation of Vasospasm
Approximately 64% (n=52) of our study patients had radiological confirmation of
vasospasm; 62 % (n=32) were in the NP group. Among vasospasm patients, there was no
statistically significant difference in the proportion of patients who had radiological
confirmation of vasospasm among the two treatment groups (P=0.959). (Table 16, Figure
17.)
Table 16: Radiological Confirmation of VSP by Treatment Groups
NP
PRAV

N
5
(14%)
3
(13%)
8

Y
32
(86%)
20
(87%)
52

Total
37
23
60
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Incidence of Radiological Confirmation of Vasospasm by
Treatment Groups
100%
95%
90%
85%

n=32

n=20

NP(N=37)

PRAV (N=23)

80%
75%
Treatment Groups
P=0.959

Figure 17: Incidence of Radiologically Confirmed Vasospasm by Treatment Groups

Elevated TCD Velocity (≥120 or Double Baseline)
Approximately 66% (n=45) of our study patients experienced elevated TCD
reading ≥120 cm/sec or had their TCD velocity double from baseline during
hospitalization; 64% (n=29) of them were in the NP group. Using Pearson chi-square test,
among the vasospasm patients, there was no statistically significant difference in the
proportion of patients who had elevated TCD velocity between the two groups (P=
0.614). (Table 17, Figure 18.)
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Table 17: Elevated TCD Velocity by Treatment Groups

NP
PRAV

N
5
(15%)
4
(20%)
9

Y
29
(85%)
16
(80%)
45

Total
34
20
54

Incidence of Elevated TCD between the Treatment
groups among Vasospasm Patients
100%
80%
60%

n=29

n=16

NP (N=34)

PRAV (N=20)

40%
20%
0%

Treatment Groups
P=0.614

Figure 18: Vasospasm Patients with Elevated TCD Velocity

Vasospasm by Angiography Report
Approximately, 35% (n=28) of our study patients had evidence of cerebral
vasospasm documented in their angiography reports; approximately 68% (n=19) of them
were in the NP group. Using Pearson chi-square test, among the vasospasm patients,
there was no statistically significant difference in the proportion of patient who had
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vasospasm documented in their angiography report between the two treatment groups
(P=0.356). (Table 18, Figure 19.)
Table 18: Angiographic VSP by Treatment Groups
N
18
(49%)
14
(61%)
32

NP
PRAV

Y
19
(51%)
9
(39%)
28

Total
37
23
60

Angiographically Confirmed Vasospasm by
Treatment Groups
60%
50%
40%
30%
20%
10%
0%

n=19
n=9

NP (N=37)

PRAV (N=23)
Treatment Groups
P=0.356

Figure 19: Angiographically Confirmed Vasospasm by Treatment Groups

Glasgow Coma Scale (GCS) Score Decline
Sixty-five percent (n=53) of the study patients experienced a drop in GCS by two
points or more; 70 % (n=37) of them were in the NP group. Using Pearson chi-square
test, among the vasospasm patients there was a statistically significant difference in the
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proportion of patient who had a GCS drop between the two groups. The proportion of
GCS drop was significantly higher in the NP group (P=0.001). (Table 19, Figure 20)
Table 19: Decline in GCS by Treatment Groups
in Vasospasm Patients
NP
PRAV

N
2
(5%)
9
(39%)
11

Y
35
(95%)
14
(61%)
49

Total
37
23
60

GCS Decline ≥ 2 Points in Vasospasm Patients
100%
80%

n=35

60%
n=14

40%
20%
0%
NP (N=37)

PRAV (N=23)
Treatment Groups
P=0.001

Figure 20: GCS Decline ≥ 2 Points by Treatment Groups in Vasospasm Patients

Triple H Therapy Use
Approximately 53% (n=43) of the study patients received triple H therapy; 74%
(n=32) of them were in the NP group. Using Pearson chi-square test, among the
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vasospasm patients, the proportion of triple H therapy use was significantly higher in the
NP group (P=0.0012). (Table 20, Figure 21.)
Table 20: Use of Triple H by Treatment Groups
NP
PRAV

N
5
(14%)
12
(52%)
17

Y
32
(86%)
11
(48%)
43

Total
37
23
60

Use of Triple H Therapy among Vasospasm Patients
100%
80%

n=32

60%
40%

n=11

20%
0%
NP (N=37)

PRAV (N=23)
Treatment Groups
P=0.001

Figure 21: Use of Triple H Therapy among Vasospasm Patients
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Number of Days to Start of Triple H Therapy across the Treatment Groups
The mean number of days to triple H therapy was 3.9 days (± SD=2.82).
Using Wilcoxon test, the median number of days from admission to triple H therapy was
significantly higher in the NP group (median=3 [Range 1-15] in NP vs. median=4 [Range
2-8] in PRAV, P=0.0438). (Figure 22)

Figure 22: Number of Days from Admission to Start of Triple H Therapy

Duration of Triple H Therapy across the Two Treatment Groups
The mean of duration of triple H therapy was 6.5 days (SD±3.92). Using
Wilcoxon test, there was no statistical significant difference in the median duration of
triple H therapy across the two groups (median=6.5 [Range 1-18] in NP vs. median=6
[Range 1-8] in PRAV, P=0.121). (Figure 23)
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Figure 23: Duration of Triple H Therapy

Screening and Building the Multivariate Models for Secondary Outcomes
In order to adjust for all potential cofounder effects on the relationship of
pravastatin on the secondary outcomes (mortality, LOS, discharge disposition, and
incidence of radiological severe vasospasm) we built a multivariate model using the same
methodology and statistical strategy we used for the primary outcome (cerebral
vasospasm). We first ran explanatory steps to describe the association of each predictor to
the outcome variables. The entrance criterion was a p-value = 0.2 and we exclude any
variable with p-value > 0.20. Then we tried to decrease the number of variables in order
to obtain a simple final model by using automatic variable selection analysis (forward
stepwise regression building analysis) with entry criteria of a significance level at 0.2.
Then we reran the analysis with the remaining selected statistically significant variables
in the model. No single variable met inclusion criteria for the multivariate model for all
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the secondary outcomes. However, we built a multivariate analysis for each outcome
adjusting for the following clinically important risk factors: race, WFNS score, number of
comorbidities, tobacco use, and clipping surgery.

Mortality
Approximately 17% (n=14) of our study patients expired during hospitalization;
64% (n=9) of them were in the PRAV group. Using Pearson chi-square test, there was no
statistically significant difference in mortality between the two treatment groups (P =
0.184). (Table 21 and 22, Figure 24.)
Table 21: Mortality
NP
PRAV

Expired
5
(12%)
9
(23%)
14

Alive Total
37
42
(88%)
30
39
(77%)
67
81
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Mortality
25%
20%

n=9

15%
10%

n=5

5%
0%
NP (N=42)

PRAV (N=39)
Treatment Groups
P= 0.184

Figure 24: Mortality across the Two Treatment Groups

Table 22: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Mortality following aSAH
Variable

Chi Square

Odds Ratio

Lower 95%

Upper 95%

p-value

Pravastatin

0.539

2.190

0.262

21.285

0.463

Race (non-AA*)

0.029

1.122

0.221

5.540

0.885

WFNS( III-V)

0.186

0.664

0.078

3.999

0.666

No. of Comorbid.(0 or 1)

0.062

0.809

0.147

4.419

0.803

Clipped

1.752

0.305

0.044

1.761

0.186

Tobacco use
*AA=African American

0.107

1.299

0.280

7.286

0.743
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The logistic regression model showed no statistically significant difference in
mortality across the two treatment groups. (Table 22) The odds of death in the PRAV
group were higher than the NP group, but it was not statistically significant. None of the
other variable had an association with mortality. (Table 22)

Discharge Disposition
Overall discharge disposition by treatment group can be found in Table 23 and
Figure 25. Of the survivors, approximately 57% (n=46) of our patients were discharged
to home; 63% (n=29) of them were in the PRAV group. Using Pearson chi-square test,
among the vasospasm patients, the proportion of patients discharged to home was higher
in the PRAV group P <0.0001. (Table 24, Figure 26.)
Table 23: Overall Discharge Disposition
NP
PRAV

Other
20
(48%)
1
(3%)
21

Home Expired
17
5
(40%)
(12%)
29
9
(74%)
(23%)
46
14

Total
42
39
81
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Overall Discharge Disposition
80%
70%
60%
50%
40%
30%

n=29

n=20
n=17
n=9

20%
10%
0%

Home
Other

n=5
n=1
NP (N=42)

Expired

PRAV (N=39)
Treatment Groups
P <0.0001

Figure 25: Overall Discharge Disposition in the Treatment Groups among All
Patients
Table 24: Survivors Discharge Disposition in
Vasospasm Patients
NP
PRAV

Other
20
(63%)
1
(5%)
21

Home
12
(37%)
18
(95%)
30

Total
32
19
51
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Survivors Discharge Disposition in Vasospasm Patients
100%
n=18

80%
60%

n=20

40%
20%

Home

n=12

Other
n=1

0%
NP (N=32)

PRAV (N=19)
Treatment Groups
P <0.0001

Figure 26: Survivors Discharge Disposition in Vasospasm Patients

Table 25: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Home Discharge Disposition Following SAH
Variable
Chi Square
Pravastatin

Odds
Ratio

Lower 95%

Upper 95%

p-value

26.703

365.466

22.511

21676.85

<.0001

No. of Co-morbid.(0
or 1)

7.133

21.515

2.129

578.246

0.008

Clipped

0.289

0.281

0.002

24.337

0.590

Race (non-AA*)

2.713

0.239

0.035

1.307

0.099

6.127

0.113

0.013

0.647

0.013

WFNS(III-V)
*AA=African American

The logistic regression model showed a statistically significant difference in the
proportion of cerebral vasospasm across the two treatment groups. The odds of being
discharged to home in the PRAV group were significantly higher than the NP group. The
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odds of having home discharge disposition in patient with 0-1 comorbidity were
significantly higher than patients with > 1 comorbidities. The odds of being discharged to
home in patients with WFNS scores of III-V were significantly less than patients with
WFNS scores of I-II. None of the other variable had an association with mortality.
(Table 25)

Table 26: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Home Discharge Disposition among Vasospasm Patients Following aSAH
Variable
Pravastatin
Clipped

Chi Square

Odds Ratio

Lower 95%

Upper 95%

p-value

16.299

43.963

5.529

1116.551

<.0001

0.045

0.677

0.0147

32.265

0.832

9.182

0.091

0.011

0.451

0.002

0.802

0.483

0.089

2.382

0.370

WFNS (III-V)
Race (non-AA*)

*AA=African American

Hospital Length of Stay (LOS)
The overall mean of length of stay for our study patients was 22.2 (SD± 22.08)
days, and the median was 15.3 (range was 3-129) days. Using Wilcoxon test, there was
no statistically significant difference in the median length of stay across the two treatment
groups; however, there was a trend toward a decreased length of stay in the PRAV group
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(median=16.8 [range 4.6-122.9] in NP vs. median=12.1 [range 3-129] in PRAV,
P=0.061). (Figure 27)

Figure 27: Hospital Length of Stay (LOS)

Table 27: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Shorter LOS Following aSAH
Variable
Pravastatin

p-value (Shorter LOS)
0.064

Race[non-AA*]

0.467

WFNS[I or II]

0.005

No. of Comorbid.[0 or 1]

0.019

Clipped

0.448

Tobacco use

0.278

Elevated WBC

0.396

*AA=African American
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The logistic regression model showed a statistically significant difference in the
LOS across the two treatment groups. The LOS was shorter in PRAV group than the NP
group. Linear multivariate regression analysis showed that patients with WFNS scores of
III-V (poorer clinical status on admission) had a longer hospital LOS, and patients with 0
-1 comorbidity had a shorter hospital LOS as reflected by their association with in the
multivariate analysis. None of the other variable had association with mortality. (Table
27)
Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS)
The overall mean NSICU-LOS was 13.5 (SD±8.72) days, and median was 11.1
(range 2.2-49.4) days. Using Wilcoxon test, there was no statistically significant
difference in the mean NSICU-LOS across the two treatment groups (median=13.1
[range 2.2-49.4] in NP vs. median= 10.1 [range 3-45] in PRAV, P=0.092). (Figure 28)

Figure 28: Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS)
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Incidence of Severe Radiological Vasospasm
Approximately 20% (n= 16) of our sample experienced severe vasospasm; 69%
(n=11) were in the NP group. Using Pearson chi-square test, among the vasospasm
patients, there was no statistically significant difference in the proportion of severe
radiological vasospasm between the two treatment groups (P=0.463). (Table 28, Figure
29.)
Table 28: Severe Vasospasm by Treatment Groups
NP
PRAV

N
26
(70%)
18
(78%)
44

Y
11
(30%)
5
(22%)
16

Total
37
23
60

Incidence of Severe Radiological Vasospasm
40%
30%
20%

n=11
n=5

10%
0%
NP (N=37)

PRAV (N=23)
Treatment Groups
P=0.463

Figure 29: Incidence of Severe Radiological Vasospasm
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Table 29: Results of the Multivariate Logistic Regression Analysis of the Predictors
of Incidence of Radiological Severe Vasospasm Following aSAH
Variable

Chi Square

Odds Ratio

Lower 95%

Upper 95%

p-value

Pravastatin

0.051

0.839

0.171

3.796

0.821

Race (non-AA*)

0.194

0.751

0.195

2.627

0.660

No. of Comorbid.(0 or 1)

0.044

1.163

0.285

4.992

0.834

WFNS (3-5)

1.486

2.290

0.605

9.262

0.223

0.006
Clipped
*AA=African American

0.976

0.152

8.133

0.980

The logistic regression model showed no statistically significant difference in the
incidence of radiological severe vasospasm across the two treatment groups. (Table 29)
The odds of developing radiological severe vasospasm in the PRAV group were lower
than the NP group, but it was not statistically significant. None of the other variable had
association with the incidence of radiological severe vasospasm. (Table 30)

Association of Cerebral Vasospasm with Mortality
Fourteen patients expired during hospitalization and approximately 64% (n=9)
experienced cerebral vasospasm. Using Pearson chi-square test, there was no statistically
significant difference in mortality based on vasospasm occurrence (p=0.358). (Table 30,
Figure 30.)
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Table 30: Mortality between Cerebral Vasospasm Groups
VSP
No VSP

Expired
9
(15%)
5
(24%)
14

Alive
51
(85%)
16
(76%)
67

Total
60
21
81

Mortality across the Two Vasospasm Groups
30%
25%
n=5

20%
15%
10%

n=9

5%
0%
VSP (N=60)

No VSP (N= 21)
Vasospasm Groups
P=0.358

Figure 30: Mortality across the Two Vasospasm Groups

Association of Cerebral Vasospasm with Discharge Disposition Outcome
One hundred percent (n=21) of survivors who were discharged to facility other
than home (rehabilitation, skilled nursing facility) experienced cerebral vasospasm. Using
Pearson chi-square test, the proportion of patients who were discharged to home was
significantly higher in the no-vasospasm group (p=0.002). The proportion of patients who
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were discharged to a facility other than home was significantly higher in the vasospasm
group. (Table 31, Figure 31.)
Table 31: Survivors’ Discharge Disposition by Cerebral Vasospasm
VSP
No VSP

Other
21
(41%)
0
(0%)
21

Home
30
(59%)
16
(100%)
46

Total
51
16
67

Axis Title

Survivors’ Discharge Disposition
across the Vasospasm Groups
120%
100%
80%
60%
40%
20%
0%

n=16
n=21
n=30
Home
n=0
No VSP (N=16)

Other
VSP (N=51)

Vasospasm Groups
P=0.002

Figure 31: Survivors’ Discharge Disposition across the Vasospasm Groups

Association of Cerebral Vasospasm with Hospital Length of Stay
Using Wilcoxon test, the median length of stay in the vasospasm group was
significantly higher than the no-vasospasm group (median=16.5 [range 3-129] in
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vasospasm group versus median=11.1 [Range 3-56.4] in no-vasospasm group, P=0.028).
(Figure 32)

Figure 32: Cerebral Vasospasm and Hospital Length of Stay

Association of Cerebral Vasospasm with Neuroscience Intensive Care Unit Length of
Stay (NSICU-LOS)
Using Wilcoxon test, the median of NSICU-LOS was significantly higher in the
vasospasm group (median=13.2 [range 3-49.4] in vasospasm group versus median=5.7
[Range 2.2-27] in no-vasospasm group, p=0.0018). (Figure 33)
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Figure 33: Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS) by
Cerebral Vasospasm

CHAPTER 4 DISCUSSIONS

The use of statins for prevention and/ or treatment of vasospasm in aSAH patients
have spread over the past several years and studying statins has been an active area of
cerebrovascular research. Statins may help to decrease the incidence of cerebral
vasospasm due to their role in improving endothelial dysfunction. To date, the use of
statins for decreasing the incidence of vasospasm after aSAH has been studied in three
prospective studies and four retrospective studies. (120-127) These studies differ from
ours in the characteristics of study population and methods, as well as results they found.
(Table 32, 33, 34, and 35)
Only two of the prospective studies showed a decrease in the incidence of
vasospasm or improved outcomes after aSAH with statins use. (120, 122, 135) The third
prospective study did not achieve statistical significance. (123) The four published
retrospective studies examined outcomes in patients who received statin therapy before
aSAH had contradictory results. Parra and colleagues found that previous statin therapy
improved functional outcomes after aSAH.(124) Another study by McGirt and colleagues
found that previous statin therapy for at least one month before aSAH and continued after
the hemorrhage (for 14 days) decreased the incidence of cerebral vasospasm by 11fold.(125) However, the study by Singhal and colleagues reported an increased risk of
66
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vasospasm in patients who had been on statin therapy before aSAH.(126) In addition,
Kramer and colleagues, recently found that statin therapy was not associated with
improved outcomes in aSAH patients.(127)
In our study, we examined the effects of pravastatin use on the incidence of
vasospasm and outcomes throughout the admission period after aSAH in a cohort of 39
aSAH patients taking pravastatin and 42 control subjects. There was no significant
difference in WFNS scores for each group (P=0.18). The proportion of patients
undergoing aneurysm clipping was higher in NP group (98% NP vs. 51% PRAV, P
<0.0001). Approximately 74% of the study patients experienced cerebral vasospasm, of
which 62% (n= 37) were in the NP group. Vasospasm was observed in 88% of patients
not taking pravastatin versus 55% taking pravastatin. Eighty five percent of patients had
symptomatic vasospasm (were diagnosed by radiological and clinical criteria).
To control for multiple variables, exclude the confounding influence of other
factors on vasospasm, and to clarify the role of these variables which are known to
impact the incidence of vasospasm, a logistic regression model was used. Although time
to surgery, elevated troponin-I, and number of comorbidities differed between the
treatment groups (intercohort differences), none of them had a significant univariate
association with vasospasm. They were, therefore, not included in the final multivariable
models. Variables were chosen from among those that were significant in the univariate
analysis of vasospasm. Vasospasm was more frequent with elevated WBC, clipping
surgery, and American African race. Although WFNS score was not associated with the

68
development of vasospasm in a univariate association, we adjusted for variations in
WFNS score because it is correlated with outcomes of aSAH. The presence of anemia
(ICD-9 code for anemia and 2 consecutive hemoglobin concentrations <10 g/dl) was
removed from the regression model as only a few patients were anemic by our definition
(n = 6) and because triple H therapy is used to induce hemodilution in aSAH patients
which would confound this variable.
The crude analysis showed that pravastatin was associated with a decrease in the
incidence of cerebral vasospasm (59% PRAV vs. 88% NP, P=0.0028). However, the
association was no longer significant after adjusting for WFNS score, race, elevated
WBC, and clipping ( P=0.08). This suggests that although there was a clinical trend
towards decreased vasospasm in the PRAV group, any benefit from pravastatin therapy
was not profound enough to remain statistically significant after other factors were taken
into account. Nevertheless, to address potential biases that may have arisen as a result of
our exclusion criteria and the lack of consistent aneurysm treatment in all patients, we
repeated the analysis both with the inclusion of clipping surgery and then without
clipping surgery. The results did change with this approach; pravastatin was associated
with a statistically significant decrease in the incidence of vasospasm if clipping was not
included. It is possible that this finding was attributed to a skewed distribution of
vasospasm in patients who received clipping surgery, which made up a majority of our
study population and accounted for almost all the NP patients. We believe that the odds
of vasospasm were affected by the type of surgical aneurysm treatment received by our

69
patients, raising the possibility that aneurysm treatment with endovascular coiling may
benefit aSAH patients.
It is important to note that there was a 29% decrease in the overall incidence of
vasospasm in the PRAV group (88% to 59%) and in the vasospasm patients; the use of
pravastatin was associated with a 27% decrease in the incidence of symptomatic
vasospasm (97% to 70%). Although, these differences were not statistically significant,
they are clinically important and support further study of statins in aSAH patients.
This study offers an important observation that elevated WBC may be associated
with vasospasm after aSAH. Logistic regression for vasospasm showed that elevated
WBC was a statistically significant factor associated with the development vasospasm.
Therefore, when the WBC count is elevated in aSAH patient, an unfavorable outcome is
more likely to occur. Some previous studies and multivariate analyses confirm these
findings, which may or may not be related to the aSAH alone. (39, 41, 42, 46, 121) It is
possible that some of the elevated WBC counts were related to infection rather than true
vasospasm, suggesting that the neuroprotective and pleiotropic effects of pravastatin may
not be observed in aSAH patients with infections or inflammatory processes.
Even though it has been suggested that WFNS, tobacco, cocaine, and alcohol use,
and younger patients have a higher tendency to suffer vasospasm, in our study we did not
find an association between vasospasm and any of these factors. A relationship between
the WFNS score at presentation and outcomes has been shown in the past. (74-77)
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Interestingly, the WFNS grade was not significantly associated with development
of vasospasm in our study. Smaller study groups like ours may underestimate these
factors and is insufficient to draw any conclusion. Also, the fact that WFNS was not
highly predictive of outcomes in the multivariate analysis suggests that secondary factors
may play a relatively more important role in the causation of poor outcomes after aSAH
other than the clinical grade at admission.
The proportion of subjects experiencing symptomatic vasospasm (clinical
vasospasm symptoms with or without associated radiological evidence of vasospasm) in
our study was 68% (n=55). The high reliability of this symptomatic vasospasm definition
reduced the likelihood of underestimating or overestimating the diagnosis of vasospasm
in our study.
Approximately 75% of our study patients experienced cerebral vasospasm. In the
NP group 88% experienced vasospasm and in the PRAV group 59% experienced
vasospasm. Moreover, the proportion of symptomatic vasospasm patients was
significantly higher in the PRAV group (97%) than NP group (70%). However, in Tseng
study, only 5% of the patients receiving pravastatin had experienced symptomatic
vasospasm, which is clearly lower than what was seen in our pravastatin patients.
Interestingly, we observed that asymptomatic cerebral vasospasm, although it was in a
small number of patients, may be increased with pravastatin use which was similar to
previous reports in the literature. (126)
Only eight patients had experienced clinical vasospasm without radiological
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evidence. In addition, nine patients had experienced GCS decline and radiological
confirmation without triple H, which were also considered to have symptomatic
vasospasm. Those patients were not on vasopressors as part of triple H therapy because
their blood pressures were already at target range.
We detected no statistically significant difference in the incidence of radiographic
vasospasm (angiographic vasospasm, elevated TCD vasospasm) or clinical vasospasm
between the treatment groups among vasospasm patients. However, pravastatin users
demonstrated a lower proportion of vasospasm confirmed by angiogram and/ or TCD,
and a lower proportion of GCS decline during the same observation period. The
difference in elevated TCD values between the two groups may be a result of differences
in their baseline TCD velocities.
Although the study design was not powered to detect a reduction in incidence of
severe vasospasm, mortality, length of hospital stay, or home discharge outcome, we
evaluated the effect of pravastatin on these outcomes.
For the incidence of severe vasospasm, after using logistic regression to adjust for
variations in race, WFNS score; number of comorbidities, and the method of aneurysm
treatment (clipping surgery), the results remained similar in univariate and multivariate
analysis. A statistically insignificant reduction (8%) in the incidence of severe
radiological vasospasm was seen in PRAV patients (from 30% in NP group to 22% in
PRAV). Larger studies are needed to confirm this trend as decreasing the incidence of
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severe vasospasm is important clinically as it could lead to severe complications like
delayed cerebral ischemia, infarction and consequently disability.
In regards to length of hospital stay, after using logistic regression to adjust for
variations in race, WFNS score, number of comorbidities, tobacco use, and the method of
aneurysm treatment (clipping surgery), the results remained similar. A trend was
observed suggesting that PRAV patients had a shorter hospital length of stay. This trend
did not, however, achieve statistical significance. Although we did not find statistically
significance difference between the two treatment groups in the hospital length of stay or
NSICU length of stay, there was a significant clinical trend in hospital length of stay and
NSICU length of stay between the vasospasm groups. This trend towards a decreased
median length of stay (median=12.1 days in PRAV vs. 16.8 days in NP, P=0.06), may
infer that pravastatin therapy may be associated with some cost savings by reducing the
intensity of inpatient requirements for managing cerebral vasospasm. Previous study
showed that cost, resource utilization and expenditures are high for treating vasospasm
after aSAH especially in the acute care setting.(136)
Furthermore, multivariate regression analysis showed that patients with WFNS
scores III-V (poorer clinical status on admission) had longer hospital LOS, and patients
with 0 or 1 comorbidity had shorter hospital LOS as reflected by their association with in
the multivariate analysis.
In regard to mortality, fourteen patients died during hospitalization. There were 9
deaths in the PRAV group and 5 in the NP group. In 5 of the 9 deaths in PRAV group,
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there was no evidence of vasospasm. These five patients had continuing poor
neurological function without evidence for vasospasm and died after withdrawal of care.
Although we did not have a large enough sample size to determine differences in
mortality, we built a logistic regression model to assess the mortality between the groups.
We adjusted for variations in race, WFNS scores, tobacco use, number of comorbidities,
and the method of aneurysm treatment (clipping surgery); the results remained similar in
univariate and multivariate analysis. There was no significant difference in mortality
between the groups (p =0.46). Our mortality result confirms the findings of Parra et al
and Chou et al studies. However, this finding contradicts the results of a prospective
study conducted by Tseng et al.
Sixty seven patients survived their hospitalization for aSAH. At discharge, most
PRAV patients achieved a favorable discharge disposition outcome, and there was
statistically significant difference between the study groups. Pravastatin was associated
with a 58% increase in the home discharge disposition for the survivors. After using
logistic regression to adjust for variations in race, WFNS scores, number of
comorbidities, and the method of aneurysm treatment (clipping surgery), the results
remained similar. In our study, pravastatin therapy was associated with better discharge
disposition in both the univariate analyses and the multivariate analysis, which raises the
possibility that immediate treatment with pravastatin after aSAH may benefit those who
survive aSAH as there was tendency toward reduced complication in the pravastatin
group.
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In addition, multivariate analysis identified that having 0 or 1 comorbidity
increased the chance of being discharged to home as compared to those having more than
1 comorbidity. Also, the analysis identified WFNS III-V as a variable decreases the home
discharge. This may infer that having more than 1 comorbidity and WFNS III-V at
admission may increase the disability at discharge.
Interestingly, when the multivariate analysis was restricted to survivors among
vasospasm patients, the effect of pravastatin on home discharge disposition slightly
decreased. However, multivariate analysis highlighted that pravastatin therapy is a
predictor of improved outcome at discharge, despite the fact that more patients in the
pravastatin group were more likely to have more than 1 comorbidity and aneurysm repair
delayed after 72 hours, which could contribute to an unfavorable outcome.
It is important to note that in the multivariate analysis for secondary outcomes,
none of the variables that we adjusted for were significantly associated with mortality or
the incidence of radiological severe vasospasm. Importantly, we found that even with
inclusion of these variables in the multivariable analyses (to correct for and eliminate
their potential bias), this did not alter the findings (significance level) in regard to the
association of pravastatin to the all secondary outcomes.
In summary, pravastatin was associated with more favorable outcomes in aSAH
patients. Generally, the observed beneficial effects (decreased trend in vasospasm and
length of stay, and significantly associated with better discharge disposition) may suggest
that the pleiotropic effects of pravastatin in aSAH patients has beneficial effects beyond
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or in addition to treating vasospasm.
These findings support the data from previous studies of pravastatin that suggest
an association with favorable outcome in aSAH patients. (120-127) Our findings are
more consistent with the findings of Parra et al and McGirt et al, demonstrating a
reduction in the incidence of vasospasm with statin use.
Although our study was in a small number of patients, it included a slightly larger
population than the previously published pravastatin Phase II randomized, controlled trial
in aSAH patients, and was adequate for statistical analysis of our primary outcome based
on our assumption that there would be a difference of 34%., (135) However, the
statistical analysis with this small number of patients has a large chance of a type II error,
in which a significant difference is lost between the PRAV and NP groups. A properly
powered study, designed to detect a 29% difference between the vasospasm incidence of
88% and 59% found in our study, should include more than 42 patients in each group.
Our sample size calculation was based upon a 34% difference in vasospasm in incidence
of statin use, which was not observed in our study.
The demographic and clinical characteristics of our patients were similar to those
of aSAH patients reported in earlier studies. To our knowledge, there were no changes in
our practice over time (Jan 2000- June 2008) that could have influenced the results. The
study patients were all admitted to neuroscience care ICU and received the same
treatments for aSAH (surgery, nimodipine, and triple H if needed) except for giving
pravastatin, which was started in 2005. Statin users represented only 48% of our aSAH
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patient sample. The most distinguished difference between groups was the type of
aneurysm treatment. After reviewing all 596 aSAH patients and applying the inclusion
and exclusion criteria for our study, significantly more PRAV patients were managed
with aneurysm coiling than NP patients in our study. This may reflect an increase use of
endovascular coiling treatment over time in our institution or selection bias. This change
in practice may have biased the results against pravastatin use and made direct
comparisons unclear and difficult. Furthermore, the quality of care of the patient may
have changed although the treatment strategy did not change during the different time
periods. Additionally, it is possible that the quality of imagining techniques used were
different in the two periods which may have influenced the radiological diagnosis of
vasospasm.
The different results in the incidence of vasospasm seen in our study as compared
to other studies may have been due to a significant difference between the two treatment
groups in the following covariates: elevated Troponin-1, clipping surgery, number of
comorbidities, and time to surgery. It is possible that these baseline differences may have
masked the favorable effects of pravastatin and increased the incidence of vasospasm.
The most significant distinction between the treatments groups was that almost all
the NP group underwent to aneurysm clipping rather than coiling (the ratio of clipped
patients to non-clipped patients was 2:1 in the NP: PRAV groups); therefore, it was
important to adjust for surgical intervention type in our multivariate logistic regression,
and also test the relation of clipping and vasospasm. In a univariate analysis, we found
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that clipping was significantly associated with an increased the incidence of vasospasm,
which we believe impacted our results. Therefore, the true effects of pravastatin cannot
be determined and may not be fully understood since the type of surgical intervention
was imbalanced. If we could remove the surgical clipping effects from the multivariate
analysis, pravastatin was associated with a decreased the incidence of vasospasm. In our
analysis, the risk of vasospasm is likely due to an imbalance (bias) in patients’ selection
in regard to the aneurysm treatment method in the two study periods. Additionally, it is
possible that the group of patients treated with clipping had a worse medical condition as
noted by the increased proportion of patients with more than 1 comorbidity. The
reduction in the volume of subarachnoid clot at the time of aneurysm treatment may also
play a role in this difference between treatment groups. However, the exact mechanism
of the relationship between aneurysm treatment methods and vasospasm in our study
population was not studied.
The choice to clip or coil is generally made by neurosurgeons. This decision may
be based on the volume of hemorrhage; degree of neurological impairment; aneurysm
location; dome, neck, and size characteristics; availability of practitioner; or any
combination of these factors. Optimal management of aneurysms remains a controversial
topic. Several papers have been published in which investigators suggest an effect of
either surgical or endovascular treatments on the development of vasospasm. (86-88)
Some retrospective, nonrandomized studies found a higher incidence of vasospasm in the
endovascular treatment group. (86, 88) However, in some of these studies, there was a
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tendency to use endovascular techniques to treat patients with a worse clinical condition
and worse degrees of aSAH. Recently, a number of investigators have reported excellent
outcomes using endovascular techniques and lower risks and complications associated
clipping surgery. To date, only one randomized study (ISAT) has been conducted in
which authors compared the outcomes of open surgery and endovascular techniques in
aSAH (The ISAT trial, 2002). In this study, endovascular treatment was associated with
a shorter LOS and a higher rate of being discharged to home. However, these data
should be further investigated.
When we restricted the analysis only to patients who were clipped, there was still
no statistical significant difference in the incidence of cerebral vasospasm across the two
treatment groups. However, the sample size was too small to compare only clipped
patients to non-clipped patients in regards to cerebral vasospasm or other outcomes. It is
very important to note that we did see a significant improvement in the incidence of
vasospasm with pravastatin when we removed clipping as a covariate from the
multivariate logistic regression analysis; removing the other covariates in the multivariate
analyses did not change the statistical significance. These results confirm that clipping
negatively impacts outcomes after aSAH. (137) Among all the previous studies, Kramer
et al. and our study are the only studies that adjusted for the type of surgical intervention.
It would be possible that if the other studies had adjusted for the effect of clipping, their
results may have changed. (Table 34)
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Triple H therapy was used for all patients with clinical vasospasm. In this study,
we found that pravastatin significantly reduced the need for use of triple H therapy in the
PRAV group. This is consistent with the assumption that statins improve the endothelial
function and reduced the inflammatory process. We measured the time to start triple H
therapy as surrogates for vasospasm onset, and number of days on triple H therapy as
surrogates for vasospasm duration, and once again detected no difference between the
treatment groups. Use of Triple H therapy was first reported an average of 4 days after
admission for the aSAH, with the majority of cases being treated between Days 3 and 4.
However, the median days to triple H therapy was significantly longer in the PRAV
group than NP group (median=3 [Range 1-15] in NP vs. median=4 [Range 2-8] in
PRAV, P=0.0438). In those whom vasospasm still occurred in the pravastatin group,
delay in the time to start triple H therapy may suggest a protective effect as seen in
previous studies. (115-119) The median duration therapy was similar in both groups
(approximately 6 days, p=0.121).
The exact explanation for why some of our findings differed from other
researches remains uncertain. However, differences in study methodology used such as
different criteria to diagnose and manage vasospasm, failure to control for confounding
variables (e.g. method of aneurysm treatment), differences in sample sizes, and different
study designs probably played a role. (Table 32-34)
Another possible explanation for our findings regarding the incidence of
vasospasm is the difference in the treatment regimen. To help avoid more confounders,
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we did not include prior statin users. Two of the three prospective studies (Chou et al. and
Tseng et al.) excluded the subjects who are on a statin prior to admission. While Lynch et
al. allowed 3 patients who were on a statin to be in the analysis. Among the retrospective
studies done to date, our study and Kramer et al. study are the only studies that excluded
any previous statin users. In those studies with previous statin users, inclusion of prior
users of statin may have contributed to favorable outcome in the statin group compared to
placebo or control. We excluded patients with prior statin use to eliminate an additional
confounding variable that may have impacted outcomes.
Additionally, there were differences among the studies in the enrollment criteria.
Cerebral vasospasm generally begins within 4-7 days after aSAH. Statin treatment was
started within 96 hours of aSAH in most of the previous studies. To avoid missing the
time window for beneficial effects, we restricted our investigation to patients who were
seen within 48 hours after aSAH and were initiated on 40mg therapy within 72 hours
aSAH. These inclusion criteria were in line with previous studies and may have
contributed to some of the beneficial effects observed in our study. (Table 28)
In addressing the potential biases that may have come up as a consequence of our
inclusion and exclusion criteria, our population was selected based on the time to
admission (within 48hours after aSAH,). This aspect affected the number of cases in our
population. We only include patients that received treatment before the high-risk period
of vasospasm in order to balance the population, which does not allow studying outcomes
that are similar to those found in the general population of patients with aSAH. Also, this
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could bias the selection of cases toward patients with less severe conditions, and may
have reduced the impact of time on the development of the vasospasm and poor outcome.
Moreover, there were differences among the studies in the length of statin therapy
evaluation. The optimal duration of statin therapy has not been determined. In our study,
the pravastatin therapy was continued until the patient was discharge from the hospital or
completed 21 days. This duration corresponds with the risk of having vasospasm up to
the three weeks after aSAH. Only 36% of our patients completed three weeks of
pravastatin therapy, with a mean of duration of pravastatin use of 13.80 days (SD ±
6.338). There was no significant difference in the incidence of vasospasm between the
two stratified durations of pravastatin use. This is consistent with studies conducted by
Tseng et al. and Lynch et al. where therapy was continued for 14 days.
One of the possible explanations for our findings regarding the incidence of
vasospasm is the difference in vasospasm definitions among all studies. The literature has
used a variety of definitions of vasospasm using terms including clinical vasospasm,
TCD vasospasm, and angiographic vasospasm. Each definition has its own strengths and
limitations. The clinical diagnosis of vasospasm is a subjective diagnosis, and the
relationship between angiographic vasospasm and clinical symptoms can be inconsistent.
It is possible that with strong clinical indications of vasospasm, that a small reduction in
the diameter of the arteries would cause a diagnosis of vasospasm in regular clinical
circumstances. The diagnosis of clinical vasospasm was based on the information
collected in the charts.
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In consideration of the limitations of a retrospective study, we made specific and
clear definition of vasospasm. We used the combined definition based on literature that
showed that the clinical factors significantly associated with vasospasm after aSAH with
TCD velocities or angiography measures improve the accuracy of cerebral vasospasm
diagnosis. Several studies have identified that the combining of radiological information
with additional clinical information could support the diagnosis of vasospasm. (50-66)
From the clinical point of view, the results of our study are useful as evidence of the
relationship between clinical, TCD and angiographic vasospasm and the nature of that
relationship.
In our study, we defined vasospasm by clinical, TCD velocity, or angiographic
criteria. Previous studies that assessed statins for the prevention of vasospasm have used
different measurements, and reported different outcomes such as incidence of
radiological vasospasm clinical and TCD velocity, a reduction in rescue therapy,
improved functional outcomes, enhanced autoregulation indices and improvement in the
duration of impaired cerebral autoregulation. (Table 32) In addition, the previous studies
have used different definitions of radiological and clinical cerebral vasospasm. (Table 33)
One example of the differences in vasospasm definition is the TCD velocity readings
interpretation. Tseng et al used mean MCA flow velocity of >120 cm/s as definition of
vasospasm, whereas Lynch et al. defined TCD vasospasm as mean MCA flow velocity of
>160 cm/s, while Chou et al. and McGirt et al, considered TCD velocity>200 as
vasospasm.
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Radiological vasospasm was identified in our study from computed tomographic
angiography or TCD velocity reports. Both Phase II trials only used TCDs to indicate
vasospasm. Using TCD velocity for diagnosis of vasospasm presents difficulty in
measurement and interpretation; however, statistically significant associations between
TCD velocities and angiography have been reported.(59, 138) Therefore, the combination
of radiological (TCD velocity and angiography) and clinical diagnosis is a powerful
predictor of vasospasm. .
Incidence of vasospasm was also relatively higher than that previously reported in
other statin studies. This is possibly explained by the definitions of vasospasm in our
main analysis. These incidences are very close to what has been published for vasospasm
(50–70%).(12, 13) Additionally, the observed reduction in vasospasm may have been to
some extent explained by an uncommonly high rate of vasospasm among NP patients
(88%).
In regard to TCD vasospasm, it is possible that some of the elevated velocities
recorded were related to hyperemia rather than vasospasm. Lindegaard ratios, which
would have allowed for such differentiation, were not recorded. TCD monitoring is an
examination that is operator dependent and requires the establishment of critical
thresholds and quality control at each institution.
The results of our study showed that cerebral vasospasm had a great impact on
aSAH patient outcomes. We found that the median hospital length of stay in the
vasospasm group was significantly higher than the no-vasospasm group (median=11.1
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[Range 3-56.4] in no-vasospasm group versus median=16.5 [range 3-129] in vasospasm
group). Similarly we found that the median NSICU-LOS was significantly longer in the
vasospasm group (median=5.7 [Range 2.2-27] in no-vasospasm group versus
median=13.2 [range 3-49.4] in vasospasm group, p=0.0018). In addition, the proportion
of patients who were discharged to a facility other than home was significantly higher in
the vasospasm group (p=0.002). All the patients who did not experience vasospasm were
discharged to home. Although, there was no statistical significant difference in
proportion of mortality between the two vasospasm groups (p=0.358), approximately
64% (n=9) of expired patients had experienced cerebral vasospasm. These observations
indicate that vasospasm is an important factor in determining the outcomes of aSAH
patients. However, it is possible that some other comorbidities, medical therapy (e.g.
triple H therapy), or medical procedures during hospitalization may have led to other
complications contributed to these poor outcomes.

Strengths and Limitations:
Strengths of our study include that 73% of vasospasm patients were diagnosed
radiologically versus clinically only. In addition, there was consistency in our diagnostic
methods and management protocol for vasospasm in aSAH during the study period.
Another strength of our study is that we are the first study to investigate the effects of
pravastatin throughout the admission period or a maximum of 21 days. We also adjusted
for potential confounding factors which appear to impact the effects of pravastatin on the
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incidence of vasospasm. A limitation of our study is that it was a retrospective design;
therefore, cause and effects cannot be determined. Additionally, we had limited
knowledge about exposure to nonprescription drugs such as cocaine, which could
increase the risk for vasospasm. It is also possible that ICD-9 coding errors resulted in
our omission of aSAH patients or the comorbidity data. Furthermore, the study only
evaluated pravastatin use and may not be able to be extrapolated to other statins. Another
limitation of this study is that the optimal dose of pravastatin in the clinical setting is not
yet determined and this may have impacted our results.
The observations in a single institute, the relatively small sample size, and the
overwhelming effects of surgical clipping on aSAH outcome affect the generalizability of
our study. Although factors commonly associated with cerebral vasospasm were
recorded and adjusted for in our analyses, the retrospective nature of this study prevents
the elimination of all possible confounding factors which could affect this analysis.
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Table 32: General Characteristics of Studies Evaluating Statin Effects in aSAH
Patients
Study
Tseng et al.
2005

Lynch et al.
2005
Chou et al.
2008
Parra et al.
2004
Singhal et al.
2005
McGirt et al.
2006
Kramer et al.
2008

Our study
2009

Design
Intervention
Sample Size
DBRCT
Pravastatin 40mg
(n=40)
Placebo, n=40
DBRCT n=39
Simvastatin 80mg
(n=19)
Placebo= 20
DBRCT
Simvastatin 80mg
(n=19)
Placebo= 20
1:2 matched
Retrospective n=60
Any statin (n=20)
Retrospectivecohort
n=514
Any statin(n=36)
Retrospectivecohort115
statin (n=15)
Retrospectivecohort n=150
Simvastatin 80m
(n=71)
Retrospectivecohort n=81
Pravastatin 40mg
n=39

Primary Objectives & Outcomes
Length of Statin Therapy Evaluation
Incidence, duration, and severity of cerebral vasospasm, and duration of impaired
autoregulation. The frequency and intensity for rescue therapy, length of inpatient stay,
Outcome at Discharge and long-term outcome at 6 months
Evaluated for 14 days
Incidence of vasospasm. Evaluated for 14 days

Death and incidence of drug morbidity. Secondary outcomes included incidence of
transcranial Doppler (TCD), angiographic or clinical vasospasm, vasospasm-related infarcts,
clinical outcomes at discharge, and cardiac and infectious morbidities. Length of evaluation
of statin therapy was not reported
Functional outcome at 14. Secondary outcomes were 14-day mortality, Modified Rankin
Scale score, DCI, cerebral infarctions of any type, and TCD highest mean velocity elevation.
Evaluated for 14 days
Risks for vasospasm, symptomatic vasospasm, and poor clinical outcomes. were evaluated
for vasospasm between days 4 and 14.
to assess factors predictive of symptomatic vasospasm
The odds of subsequent symptomatic vasospasm onset. Evaluated through hospital stay.
The occurrence of vasospasm, delayed infarction, or poor outcome (death, vegetative state, or
severe disability). Evaluated for 14 days

Incidence of vasospasm, incidence of severe vasospasm, mortality, length of stay, clinical
outcomes at discharge. Evaluated Until discharge from hospital, or a maximum of 21 days.

DBRCT=Double Blind Randomized Clinical Trial
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Table 33: Cerebral Vasospasm Definitions in Studies Evaluating Statin Effects in
aSAH Patients
.
Tseng et al.
Lynch et al.

Chou et al.

Parra et al.
Singhal et al.

Cerebral
Vasospasm
Criteria
Radiological
only
Radiological
and
biochemical
markers
Radiological
only

Clinical
Definition

Radiological Definition

NR

>120 cm/s with Lindegaard ratio (LR) > 3.

Clinical impression of a delayed ischemic
neurological deficit

TCD MCA >160 m/sec by TCD or
Angiography

NR

Radiological
only
Radiologic and
clinical

NR

Angiographic vasospasm was defined as focal or
reduction of cerebral arterial caliber on conventional
cerebral angiogram. TCD MCA >200 cm/s and a
Lindegaard ratio of >3.
TCD-HMV is ≥120 cm/s or angiograph, TCD-HMV
change of ≥50 cm/s
TCDs for the basilar artery are ≥120. TCD for other
cerebral arteries ≥200 cm/second values, Lindegaard’s
ratio was used.

McGirst et al.

Radiologic and
clinical

Kramer et al.

Reported as
Radiological
or clinical
Radiologic
and/or clinical

Our study

NR= Not reported

Symptomatic vasospasm was defined as a
focal neurologic deficit in the territory of the
basal or cortical arteries
or a decline in level of consciousness; the
neurologic worsening had to be associated
with cerebral vasospasm
Either angiographic vasospasm or the TCD ≥
200 cm/second and neurological
improvement was
observed during triple-H therapy.
Neurological deterioration, radiographic
vasospasm, physician decision to treat.
Received 2 of the 3 aspects of triple-H
therapy, onset of neurological deficit or
change of neurological deficit severity, or
drop in Glasgow Coma Scale by ≥ 2 points

Cerebral vasospasm was diagnosed in patients with
DINDs if they improved with triple-H therapy and
their TCD ultrasonography flow velocities were >200
cm/second, or angiographic VSP despite partial or no
response to triple-H therapy.
Angiographic >30% narrowing.
TCD double of the baseline value or are > 120 cm/sec;
or angiographic vasospasm
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Table 34: Method Characteristics of all the Studies Evaluating Statin Effects in SAH
Outcomes to Date

.

Included
Previous
Statin
Users

Enrollment
Time Criteria

Clipped

Coiled

No surgical
intervention

Statistical
Adjustment
for Clipping

Tseng et al.

No

≤ 72 hrs.

Placebo: 15%
Prav: 17.5%
P= 0.686

Yes,
n=3

NR

Placebo:
22.5%
Prav: 15%
P= 0.686
0

No

Lynch et al

No

Chou et al.

No

≤ 96 hours

NR

NR

No

Parra et al.

Yes,
n=25

≤ 14 days

No

Yes,
n=19

≤ 14 days

NR

No

McGirt et al.
Kramer et al.

Yes
Yes,
n=5

Stated equal
number in
each groups
Coiled 19%
Clipped and
coiled 1%
Detail NR
NR
Control:(33%)
Sim.: (55%)
P = <0.01

0

Singhal et al.

Placebo:
62.5%
Prav: 67.5%
P= 0.686
Placebo:
40%
Sim.: 47%
Placebo:
(80%)
Sim.:
(89%)
Stated equal
number in
each groups
Clipped
80%
Detail NR

NR
Five patients

No
Yes

Control: 2%
Prav: 26%

Control:0%
Prav:25%

Yes

NR

NR
Control
:(63%)
Sim. (42%)
P = <0.01
Our study
No
Control:
≤ 48 hrs
98%
Prav: 51%
p <0.0001
Prav= pravastatin, Sim= simvastatin, NR= not reported
≤ 72 hours

Placebo: 60%
Sim.: 53%
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Table 35: Results of all Studies Evaluating Statin Effects in SAH Outcomes to Date
Study

Incidence of
Any VSP
or Radiological
VSP
Tseng et al. Placebo: 62.5
Prav: 42.5%
P= 0.006
Lynch et al. Placebo=60%
Sim=26%
P= 0.03
Chou et al. Radiological
Placebo: (50%)
Sim: (68%)
P=0.24

Incidence of Incidence of
Symptomatic Severity or Severe
VSP
VSP

LOS

Mortality

Length of Triple H
Therapy

Outcome at
discharge

NR

NSDF

NR

NSDF

NR

Placebo:20%
Prav: 5%
P= 0.037
NR

NR

NR

Parra et al.

Control: 51%
Statin: 18%
P=0.03

Singhal et al. Univaraite User:
OR 2.25 CI
(0.97–5.83) p=
0.05
Univaraite Statin
discontinued: OR:
2.35
CI (0.74–9.88)
P= 0.15
All vasospasm 319
(62%)

NR

Placebo 30%
Prav: 17.5%
P= 0.044
NR

NR

NR

Placebo: 18±9
Sim: 20±12
P= 0.74

Placeb: 15%
Sim: 0%
P= 0.23

Placebo: Median=2
Sim. Median=2
P= 0.86

To home
Plac: 35%
Sim: 42%
P= 0.65

NR

NR

NR

Control:13%
Statin: 20%
P= 0.46

NR

NR
Univaraite
User:
OR 1.62 CI
(0.74–3.41)
0.18
univaraite
Statin
discontinued:
OR OR 2.28
CI (0.80–6.34)
P=0.12

NR

Statin group
NR
OR: 0.44
CI (0.14–1.40)
P= 0.17
All death:
12%

Used MRS, BI,
and
Lawton-PSMS
scores.
Used MRS

NR

NR

NR

Control: 42%
Sim: 41%
Simvastatin
did not decrease
radiographic
moderate to severe
VSP

NR

McGirt et al. Used sym. as
Control: 48%
definition for VSP Statin: 6.6%
P= 0.002
Kramer et al. Radiological:
Plac: 20 (25%)
Control: 33 (42%) Sim: 23 (32%)
Sim: 29 (41%)
P= 0.34
P= 0.91
(Reported as radio
and clinical VSP)

Our study

Control: 88%
Prav: 59%
Adjusted P=0.25

Control: 86% Control: 26%
Prav: 42%
Prav: 13%
P=0.002
P=0.463

Control:
median=16.8
Prav:
median=12.1
P=0.061

NR

NR

NR

Poor outcome
was defined as a
GOS score of 1-3
(death,
vegetative state,
or severe
disability)

Control: 12% Control: Median=6.5 days Control: 40%
Prav: 23%
Prav: Medians=6 days
Prav: 74%
P=0.184
P= 0.121
P<0.0001

VSP= vasospasm, Modified Rankin Scale (MRS), Barthel Index (BI), and Modified Lawton Physical Self Maintenance Scale (Lawton-PSMS), Prav=
pravastatin, Simv= simvastatin, NR= not reported
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CHAPTER 5 CONCLUSIONS

We concluded that there was a trend towards a decrease in the incidence of
vasospasm in the aSAH receiving pravastatin, but this trend did not achieve statistical
significance after adjusting for potential confounders. Pravastatin therapy was not
associated with a decrease in the incidence of radiological severe vasospasm or a
reduction in mortality in aSAH patients. Although, the effect of pravastatin was not to the
same degree and extent of positive effects as shown by earlier studies, pravastatin
appeared to provide some other clinical benefit. We did demonstrate a trend toward a
decrease in hospital LOS and a significant favorable discharge disposition in patients who
received pravastatin therapy, so one possible conclusion is that they have other beneficial
effects in addition to treating vasospasm. We believe the pleiotropic effects of pravastatin
may be responsible for some of the observed favorable (protective) benefits after aSAH
as seen in the pravastatin group in this study.
Also, favorable outcomes were more likely in patients whose aneurysms are
coiled rather than clipped in our study. The clinical value of statin therapy initiated after
aSAH remains unclear because surgical clipping was done for 98% of NP treated patients
and 51% of PRAV patients and this may have impacted our results. However, our
results showed that among the PRAV group, the proportion of patients who experienced
vasospasm was significantly higher in the clipped group as compared to non-clipped
group, which suggest that there may be an effect of pravastatin on vasospasm if patient
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were not clipped. Despite the limitations of this investigation, the results of this study
support the use of statins in aSAH and the main findings from this analysis will have
important implications for the treatment of aSAH. Further investigation of statin therapy
for the prevention and treatment of cerebral vasospasm is needed.

Future Direction
The results of this analysis are encouraging and interesting. More information is
required before any therapeutic recommendation can be fully supported. Cerebral
vasospasm is a not fully understood complication and is associated with many different
factors. Studying the pathophysiology of vasospasm can provide key pathways for future
research. Although we found that pravastatin treatment was not statistically associated
incidence of vasospasm, prospective multicenter controlled studies are needed to validate
our findings, to better evaluate the potential benefits of statins in the treatment of aSAH,
and to determine optimal dosage, choice of statins, and duration of treatment. Although
the association of elevated WBC with vasospasm confirms findings of previous studies,
(46) further research into the duration of therapy and conditions that may be associated
with vasospasm should also be considered.
Once the advantages of clipping and non-clipping surgery in aSAH patients are
established, the possible benefit of starting a statin after aSAH should be considered. It
will be very interesting to see the long-term protective effect of statins after following-up
of these patients and assessing their outcomes at 1 year after the aSAH.
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